Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Traws Pharma Inc's Competitiveness

Name: Traws Pharma Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Traws Pharma Inc (TRAW) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q2 2026

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/TRAW/competitors                    

                        https://api.csimarket.com/api/v1/companies/TRAW/relationships                    

                        https://api.csimarket.com/api/v1/companies/TRAW/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Traws Pharma Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Traws Pharma inc	-	-	-	Yes
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

TRAW Stock Performance relative to its Competitors

TRAW Competitors (weighted) Percent change over the selected range

Traws Pharma Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Similar-Size
(1 of 10)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Traws Pharma inc	-70.50 %	Underperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (10)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Traws Pharma Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

TRAW Stock Performance relative to Similar-Size Competitors

TRAW Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Traws Pharma Inc's Comment on Competition and Industry Peers

The company operates in the biotechnology and pharmaceutical industries, which are characterized by rapid technological changes and intense competition. Competitors include large and small pharmaceutical and biotechnology companies, as well as public and private universities and research organizations. Many competitors are multinational organizations developing or marketing pharmaceuticals targeting viruses, oncology indications, or cellular pathways. These competitors typically possess greater financial, technical, and human resources, along with more experience in product discovery, development, regulatory approvals, and commercialization. The company expects competition to intensify as new drugs and advanced technologies emerge. Various drugs are currently approved for the treatment of influenza, including neuraminidase inhibitors, with related patents listed in the FDA's Orange Book. These listings can be utilized by competitors to support abbreviated new drug applications or 505(b)(2) applications. The Orange Book Transparency Act of 2020 codified FDA practices regarding patent listings, and in 2023, the Federal Trade Commission sent letters to several companies concerning anticompetitive conduct related to patent listings.

Competitor data is not yet available for Traws Pharma Inc.

Traws Pharma Inc's Business Segment Mix vs Peers

Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).

Company	Largest Segment	2nd Segment	3rd Segment
Traws Pharma inc	Single reportable segment 100.00 %	-	-

Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).